|
Q-ETA Enzyme immunoassay for the quantitative determination of Etanercept (Enbrel®) in serum and plasma
Etanercept specific monoclonal antibody based Enzyme immunoassay for the quantitative determination of etanercept (Enbrel®) in serum and plasma samples between the Cmin and Cmax range of concentrations as indicated. The user-friendly Matriks Biotek Q-ETA is the first and only ELISA kit in the market for the quantitative determination of etanercept (Enbrel®) at uppermost specificity. Sample volume: 20 μL Total Test Reaction Time: 160 min.
S-ATE Enzyme immunoassay for the qualitative determination (screening) of antibodies to etanercept in serum and plasma The Matriks Biotek Antibody to Etanercept ELISA Kit can be efficiently used for monitoring anti-Etanercept antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-etanercept antibodies. Sample volume: 10 μL Total Test Reaction Time: 140 min. |
|
QS-INFLIXI Enzyme immunoassay for the specific quantitative determination of Infliximab (Remicade®) in serum, plasma and other biological fluids Sample volume: 10 μL Total Test Reaction Time: 75 min.
Matriks Biotek Infliximab ELISA is developed for specific measurement of Infliximab (Remicade®) in sera, plasma and other biological fluids by the advantage of using a site-directed monoclonal antibody specific for Infliximab (Remicade®) only. The user-friendly Matriks Biotek Specific Infliximab ELISA is the first and only ELISA kit for the quantitative determination of Infliximab (Remicade®) at uppermost specificity.
Q-INFLIXI Enzyme immunoassay for the quantitative determination of infliximab (Remicade®) in serum and plasma Sample volume: 10 μL Total Test Reaction Time: 55 min.
Q-ATI Enzyme immunoassay for the qualitative and quantitative determination of specific antibodies to infliximab in human serum and plasma. Sample volume: 10 μL Total Test Reaction Time: 140 min.
“USE YOUR DRUG EFFECTIVELY AND SAFELY”
Follow-up your patient’s trough infliximab levels, dose response to infliximab with QS-INFLIXI and adjust dose when needed.
Check anti-infliximab antibodies in your patients sera with Q-ATI , escalate the dose or combine with (e.g.) methotrexate when needed.
|
|
Q-ADA Enzyme immunoassay for the quantitative determination of free adalimumab (Humira®) in serum and plasma. Matriks Biotek adalimumab ELISA has been especially developed for the quantitative analysis of free adalimumab in serum and plasma samples. Sample volume: 20 μL Total Test Reaction Time: 70 min.
S-ATA Enzyme immunoassay for the qualitative determination (screening) of antibodies to adalimumab in serum and plasma. Adalimumab (Humira®) was associated to the development of anti-Adalimumab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Humira®. This might lead to severe complications. The Matriks Biotek Antibody to Adalimumab ELISA Kit can be efficiently used for monitoring anti-Adalimumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Adalimumab antibodies. Sample volume: 10 μL Total Test Reaction Time: 140 min. |
|
innovation for health & wellness |
|
Matriks Biyoteknoloji Ltd., as a biotechnology company is committed to R&D and production of immune based molecules and tools for the life science community. We produce recombinant proteins, monoclonal antibodies to have a better understanding of human related diseases.
The use of humanized recombinant monoclonal antibodies in certain diseases as biopharmaceuticals arouse the question of effectiveness in each individual treated person. We offer specific ELISA kits for the quantitative determination anti-TNF antibodies and blockers ( infliximab, adalimumab and etanercept). Several molecules are in R&D phase in the prospect of our companies research interests (for more please refer to R&D section). |
|
Specialized in TNF and related tests we offer ELISA kits for the quantitative/qualitative determination of TNF, TNF blockers and anti-TNF blockers |
|
pharmacokinetic studies
Researchers can estimate infliximab, etanercept and adalimumab levels in human, mouse, rat and monkey serum samples for pharmacokinetic studies by using relevant Matriks Biotek ELISA kits. |
|
Q-TNF Enzyme immunoassay for the quantitative determination of Human Tumor Necrosis Factor-alpha (TNF-α) in serum, plasma and cell culture supernatants. The Matriks Biotek sensitive and specific TNF-α determination kit is based on double monoclonal antibody sandwich assay where TNF-α is captured with one monoclonal antibody on to solid phase and detected by another monoclonal antibody labeled with horse raddish peroxidase. For more information please refer to Instructions for Use PDF file. Sample volume: 50 μL Total Test Reaction Time: 200 min.
|
|
Matriks Biotek introduces two new ELISA kits for:
1. Enzyme immunoassay for the specific quantitative determination of Infliximab (Remicade®) the first and only ELISA kit in the market for the specific quantitative determination of Infliximab (Remicade®)at uppermost specificity. 2. Enzyme Immunoassay (ELISA) for the Quantification of Human Soluble TNF-RII |
|
Q-sTNF-RII Enzyme Immunoassay (ELISA) for the Quantification of Human Soluble TNF-RII (p75/80 kDa) from Cell Culture Supernatant, Serum, Plasma or Other Body Fluids Sample volume: 20 μL Total Test Reaction Time: 80 min.
This immunoassay has been designed to accurately quantitate the recombinant as well as native human soluble TNF-RII (p75/80). Since the measurement of human sTNF-RII by the Human sTNF-RII Immunoassay is insensitive to added TNF and this measurement corresponds to the total amount of the sTNF-RII present in samples, i.e., the total amount of free sTNF-RII plus the total amount of sTNF-RII bound to TNF.
|
